| 2017-05-16 06:31:50 | Edwards Lifesciences initiated with a Conviction Buy at Goldman SachsGoldman Sachs analyst Isaac Ro started Edwards Lifesciences with a Conviction Buy rating and $138 price target. Investors should own the "dominant player" in the expanding transcatheter aortic valve replacement market, the analyst contends. | |
|---|---|---|
| ||
| , … |
| |
|---|---|---|
| ||
| | |
| | |
| |
| | |
| ||
| | |
| , |
| |
| , |
| |
| ||
| | |
| , … |
| |
| , |
| |
| |
| , … |
| |
|---|---|---|
| | |
| | |
| ||
| |
| | |
| , |
| |
| ||
| ||
|